Table 2.
Univariate and multivariate analysis for factors associated with internal mammary lymph node (IMLN) metastasis.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
|
OR (95% CI) |
P-value |
OR (95% CI) |
P-value | |
| Age | ||||
| ≤ 40 | 1 | |||
| >40 | 1.207 (0.392–3.712) | 0.743 | ||
| Tumor size | ||||
| T1 | 1 | 1 | ||
| T2 | 1.372 (0.516–3.651) | 0.527 | 2.183 (0.553–8.628) | 0.265 |
| T3 | 26.250 (2.807–25.523) | 0.004 | 12.114 (0.550–26.687) | 0.114 |
| Tumor location | ||||
| UIQ | 1 | 1 | ||
| LIQ | 1.543 (0.438–5.439) | 0.5 | 0.864 (0.144–5.181) | 0.873 |
| Central | 1.800 (0.322–10.055) | 0.503 | 0.146 (0.008–2.778) | 0.201 |
| UOQ | 0.300 (0.096–0.936) | 0.038 | 0.098 (0.020–0.486) | 0.004 |
| LOQ | 0.360 (0.038–3.374) | 0.371 | 0.051 (0.001–3.823) | 0.177 |
| ER | ||||
| Negative | 1 | |||
| Positive | 0.919 (0.378–2.231) | 0.851 | ||
| PR | ||||
| Negative | 1 | |||
| Positive | 0.939 (0.379–2.324) | 0.891 | ||
| Her2 | ||||
| Negative | 1 | |||
| Positive | 1.187 (0.399–3.533) | 0.758 | ||
| Others | 1.543 (0.338–7.037) | 0.575 | ||
| LVI | ||||
| Negative | 1 | 1 | ||
| Positive | 12.571 (4.179–37.817) | 0.000007 | 12.571 (4.179–37.817) | 0.000007 |
| pALN stage | ||||
| N0 | 1 | 1 | ||
| N1 | 2.864 (0.903–9.086) | 0.074 | 5.399 (1.224–23.812) | 0.026 |
| N2 | 8.167 (2.042-12.654) |
0.003 | 9.458 (1.711–22.293) | 0.010 |
| N3 | 28.000 (14.770–44.371) | 0.000224 | 53.219 (12.772–68.245) | 0.022 |
| NAC received | ||||
| No | 1 | |||
| Yes | 0.957 (0.175–5.229) | 0.960 | ||
| Imaging-reported IMLN status | ||||
| Negative | 1 | |||
| Positive | 1.261 (0.451–3.524) | 0.658 | ||
ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor-2; UIQ, upper inner quadrant; LIQ, lower inner quadrant; UOQ, upper outer quadrant; LOQ, lower outer quadrant; LVI, lymphvascular invasion; pALN, pathological axillary lymph node; pIMLN, pathological internal mammary lymph node; NAC, Neoadjuvant chemotherapy.